The U.S. FDA's first approval of recombinant human growth hormone (rHGH) in 1985 was an important milestone and a breakthrough in the treatment of patients with GHD (growth hormone deficiency), a disease caused by a lack of adequate growth hormone in the body, primarily in children and adolescents. Previously, GHD patients could only be treated with injections of growth hormone extracted from humans or animals, which had many risks and limitations. Growth hormone produced by recombinant DNA technology offers a safer and more effective treatment for GHD patients.
Recombinant growth hormone is a genetically engineered synthetic protein that is structurally and functionally similar to the growth hormone secreted by the human body. This technological breakthrough has enabled scientists to mass-produce this growth hormone in the laboratory, thus providing a stable and reliable supply for GHD patients. With the approval of the FDA, recombinant growth hormone has successfully moved out of the laboratory and become a widely used drug, bringing health and hope to countless GHD patients.
Since 1985, the use of recombinant human growth hormone has been expanding, not only in the treatment of GHD patients, but also in the treatment of several other growth disorders and metabolic abnormalities. At the same time, scientists are also exploring other potential applications of recombinant human growth hormone, such as in sports medicine and geriatric health.
However, the use of recombinant growth hormone also faces some controversies and challenges. There are concerns that the excessive use of growth hormone may adversely affect the growth and development of children and adolescents; there are also concerns that the abuse of growth hormone in the sports sector and competitive sports may result in unfair competition. In view of this, the regulatory bodies and the medical profession have been working hard to formulate more stringent guidelines on the use of growth hormone and regulatory measures to ensure the rational and safe use of growth hormone in recombinant growth hormone.
In conclusion, the introduction and FDA approval of recombinant human growth hormone has brought a ray of hope for the treatment of GHD patients and other related diseases, and has also inspired scientists to explore and innovate in genetic engineering and biotechnology. With the continuous progress of science and technology, we have reason to believe that recombinant human growth hormone will play an even more important role in the future, bringing more hope and possibilities to the cause of human health.
EN 
ZH_TW 
ZH